|
|
Therapeutic Protein Industry, Value MappingPublished by: Credolegal Oy Published: Nov. 17, 2004 - 14 Pages Table of Contents1.0 Background to therapeutic proteins and their manufacturing 2.0 Key findings related to monoclonal antibody production and industry positions 3.0 Pharmaceutical value chain, profit gaining opportunity for Transgenic Manufacturers Table I. Table II. Table III. Table IV. AbstractMany players in the pharmaceutical value-chain have announced that their long-term objective is to become a leader in the generation, development and commercialization of novel antibody-based biopharmaceutical products and to become fully integrated pharmaceutical companies. The following findings will clarify the position of various industry players:
a) Antibody discovery companies aim to build a large and diversified product portfolio, including a mix of out-licensed and internally developed product candidates, by utilizing several technologies.
b) Target validation plays a key role in more than 25% of the large pharmaceutical genomic-related deals announced during the last two years.
c) We believe the speed and cost advantages of antibody discovery companies gained through their core technologies (for example phage display technology) will enable them to make cost-effective use of available human and capital resources.
d) Antibody discovery companies generate revenues by out-licensing their core technologies and by in-licensing or acquiring proprietary product candidates.
e) Scientific research studies are taking place to overcome the problem of protein delivery inside cells.
f) Risk-reducing technologies are constantly being developed to overcome problems related to monoclonal antibody production.
|
|
|||
|
About MarketResearch.com
|
||||